The effect of basal–bolus therapy varies with baseline 1,5‐anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis

To investigate the impact of baseline 1,5‐anhydroglucitol on the treatment effect of basal–bolus therapy in people with Type 2 diabetes.

[1]  Y. Bao,et al.  The metabolism and transport of 1,5-anhydroglucitol in cells , 2018, Acta Diabetologica.

[2]  H. Rodbard,et al.  Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18‐week, open‐label, phase 3 trial (onset 3) , 2017, Diabetes, obesity & metabolism.

[3]  T. Pieber,et al.  A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes , 2017, Clinical Pharmacokinetics.

[4]  K. Khunti,et al.  Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin , 2016, Diabetes, obesity & metabolism.

[5]  J. Pankow,et al.  Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality , 2015, Diabetes.

[6]  R. Klein,et al.  Association of 1,5-anhydroglucitol with diabetes and microvascular conditions. , 2014, Clinical chemistry.

[7]  W. Herman,et al.  Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. , 2012, Diabetes research and clinical practice.

[8]  M. Zwahlen,et al.  Association of 1,5-Anhydroglucitol and 2-h Postprandial Blood Glucose in Type 2 Diabetic Patients , 2008, Diabetes Care.

[9]  M. Zwahlen,et al.  Association of 1,5-Anhydroglucitol and 2-h Postprandial Blood Glucose in Type 2 Diabetic Patients , 2008, Diabetes Care.

[10]  K. Dungan.  1,5-anhydroglucitol (GlycoMark™) as a marker of short-term glycemic control and glycemic excursions , 2008, Expert review of molecular diagnostics.

[11]  B. Göke,et al.  Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. , 2007, Diabetes research and clinical practice.

[12]  Janet B McGill,et al.  Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. , 2004, Diabetes care.

[13]  W. Alexander,et al.  American diabetes association. , 2010, P & T : a peer-reviewed journal for formulary management.

[14]  J. McGill,et al.  Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. , 2003, Diabetes technology & therapeutics.